XOMA/$XOMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About XOMA
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
Ticker
$XOMA
Sector
Primary listing
Employees
14
Headquarters
Website
XOMA Metrics
BasicAdvanced
$523m
26.47
$1.58
0.90
-
Price and volume
Market cap
$523m
Beta
0.9
52-week high
$42.81
52-week low
$22.29
Average daily volume
306k
Financial strength
Current ratio
3.59
Quick ratio
3.308
Long term debt to equity
95.954
Total debt to equity
110.485
Dividend payout ratio (TTM)
16.35%
Interest coverage (TTM)
0.38%
Profitability
EBITDA (TTM)
8.295
Gross margin (TTM)
99.04%
Net profit margin (TTM)
69.63%
Operating margin (TTM)
10.25%
Effective tax rate (TTM)
0.31%
Revenue per employee (TTM)
$3,470,000
Management effectiveness
Return on assets (TTM)
1.28%
Return on equity (TTM)
34.23%
Valuation
Price to earnings (TTM)
26.47
Price to revenue (TTM)
10.364
Price to book
5.35
Price to tangible book (TTM)
10.15
Price to free cash flow (TTM)
-25.861
Free cash flow yield (TTM)
-3.87%
Free cash flow per share (TTM)
-1.613
Growth
Revenue change (TTM)
13.16%
Earnings per share change (TTM)
-260.07%
3-year revenue growth (CAGR)
143.65%
10-year revenue growth (CAGR)
-1.55%
3-year earnings per share growth (CAGR)
-15.74%
10-year earnings per share growth (CAGR)
2.56%
What the Analysts think about XOMA
Analyst ratings (Buy, Hold, Sell) for XOMA stock.
XOMA Financial Performance
Revenues and expenses
XOMA Earnings Performance
Company profitability
XOMA News
AllArticlesVideos
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
Business Wire·4 weeks ago
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
Benzinga·4 weeks ago
XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs